Reverse sandwich immunoassay

• US 4,098,876 A
• Filed: 10/26/1976
• Issued: 07/04/1978
• Est. Priority Date: 10/26/1976
• Status: Expired due to Term

• Current Assignee: CIBA Vision Corporation (Novartis Ag)
• Original Assignee: Corning Glass Works (Corning Incorporated)
• Inventors: Ryan, James W., Woiszwillo, James E., Piasio, Roger N.
• Primary Examiner(s): Padgett, Benjamin R.
• Assistant Examiner(s): Nucker, Christine M.
• Application Number:
  US05/735,740
• Time in Patent Office: 616 Days
• Field of Search: 424/1, 424/1.5, 424/12, 23/230 B
• US Class Current: 436/500
• CPC Class Codes: G01N 2470/04 Sandwich assay format
• CPC Class Codes: G01N 33/538 by sorbent column, particles or resin strip , i.e. sorbent materials
• CPC Class Codes: G01N 33/54306 Solid-phase reaction mechanisms
• CPC Class Codes: G01N 33/552 Glass or silica
• CPC Class Codes: G01N 33/78 Thyroid gland hormones , e.g. T3, T4, TBH, TBG or their receptors
• CPC Class Codes: Y10S 436/82 Hepatitis associated antigens and antibodies

Abstract

Method of determining the presence and/or concentration of a polyvalent antigenic substance in a fluid. The method comprises the steps of incubating the fluid with labeled antibodies to the substance to form a first labeled immunochemical complex and then incubating that complex with immobilized antibodies to the substance to form a second labeled complex which is separated from the incubation medium. The amount of label in the second complex provides a means for detecting and/or quantitating the substance in the fluid. By reversing the sequence of incubation steps in a "two-site" or sandwich assay, greater sensitivity is achieved and an intermediate washing step is eliminated.

Claims

1. A method of determining the presence or concentration of a polyvalent antigenic substance in a fluid sample which comprises the steps of:

(a) incubating the fluid sample with labeled antibodies to the substance under conditions sufficient to form a first labeled immunochemical complex;

(b) incubating that complex with a composite comprising antibodies to the substance immobilized on a water insoluble carrier material, the incubation being under conditions sufficient to form a second labeled complex comprising the first complex complexed to the composite;

(c) separating the second labeled complex from the incubation medium;

(d) determining the amount of label associated with the second complex;

(e) relating the determination of step (d) to a standard to determine the presence or concentration of the substance in the fluid.

2. The method of claim 1 wherein the labeled antibodies of step (a) are labeled with an enzyme.

3. The method of claim 1 wherein the labeled antibodies of step (a) are labeled with a fluorogenic material.

4. The method of claim 1 wherein the labeled antibodies of step (a) are labeled with a radioisotope.

5. The method of claim 1 wherein the composite of step (b) comprises antibodies immobilized on an organic carrier.

6. The method of claim 1 wherein the composite of step (b) comprises antibodies immobilized on an inorganic carrier.

7. The method of claim 6 wherein the carrier comprises glass particles.

8. The method of claim 1 wherein the determination of step (d) is done enzymatically.

9. The method of claim 1 wherein the determination of step (d) is done fluorometrically.

10. The method of claim 1 wherein the determination of step (d) is done radiometrically.

11. A method of determining the concentration of thyroid stimulating hormone in a human body fluid, the method comprising the steps of:

(a) incubating the fluid with labeled antibodies to thyroid stimulating hormone under conditions sufficient to complex substantially all of the hormone in the fluid with the antibodies;

(b) incubating the complexes of step (a) with a composite comprising antibodies to the hormone attached to a water insoluble carrier material, the incubation being under conditions sufficient to assure complexation of substantially all of the labeled complex of step (a) with the composite;

(c) separating the incubation products of step (b) from the incubation medium;

(d) determining the amount of label associated with the separated products; and

(e) relating that determination to a standard to determine the concentration of the thyroid stimulating hormone.

12. The method of claim 11 wherein the labeled antibodies of step (a) are labeled with an enzyme.

13. The method of claim 11 wherein the labeled antibodies of step (a) are labeled with a fluorogenic material.

14. The method of claim 11 wherein the labeled antibodies of step (a) are labeled with a radioisotope.

15. The method of claim 11 wherein the composite of step (b) comprises antibodies immobilized on an organic carrier.

16. The method of claim 11 wherein the composite of step (b) comprises antibodies immobilized on an inorganic carrier.

17. The method of claim 16 wherein the carrier comprises glass particles.

18. A method of detecting the presence of hepatitis associated antigen in a human body fluid, the method comprising the steps of:

(a) incubating the fluid with labeled antibodies to the antigen, the incubation being under conditions sufficient to complex any antigen in the fluid with the labeled antibodies;

(b) incubating the complex of step (a) with a composite comprising antibodies to the antigen immobilized on a water insoluble carrier material, the incubation being under conditions sufficient to complex at least a portion of the complex of step (a) with the composite;

(c) separating the incubation products of step (b) from the incubation medium;

(d) determining the amount of label associated with the separated incubation products; and

(e) relating the determination of step (d) to a standard to determine if the antigen is present in the sample.

19. The method of claim 18 wherein the labeled antibodies of step (a) are labeled with an enzyme.

20. The method of claim 18 wherein the labeled antibodies of step (a) are labeled with a fluorogenic material.

21. The method of claim 18 wherein the labeled antibodies of step (a) are labeled with a radioisotope.

22. The method of claim 18 wherein the composite of step (b) comprises antibodies to hepatitis associated antigen immobilized on an organic carrier.

23. The method of claim 18 wherein the composite of step (b) comprises antibodies to hepatitis associated antigens immobilized on an inorganic carrier.

24. The method of claim 23 wherein the inorganic carrier comprises glass particles.

25. A method of determining the concentration of carcinoembryonic antigen in a body fluid, the method comprising the steps of:

(a) incubating the fluid with labeled antibodies to carcinoembryonic antigen under conditions sufficient to complex the antigen with the antibodies;

(b) incubating the complexed products of step (a) with a composite comprising antibodies to carcinoembryonic antigen immobilized on a water insoluble carrier material, the incubation being under conditions sufficient to assure complexation of the complex of step (a) with the composite;

(c) separating the incubation products of step (b) from the incubation medium;

(d) determining the amount of label associated with the separated products; and

(e) relating the determination of step (d) to a standard to determine the concentration of the antigen.

26. The method of claim 25 wherein the labeled antibodies of step (a) are labeled with an enzyme.

27. The method of claim 25 wherein the labeled antibodies of step (a) are labeled with a fluorogenic material.

28. The method of claim 25 wherein the labeled antibodies of step (a) are labeled with a radioisotope.

29. The method of claim 25 wherein the composite of step (b) comprises antibodies to the antigen immobilized on an organic carrier.

30. The method of claim 25 wherein the composite of step (b) comprises antibodies to the antigen immobilized on an inorganic carrier.

31. The method of claim 30 wherein the carrier comprises glass particles.